[Los Angeles] The Future of Psychedelic Medicine in Los Angeles

Psychedelic Los Angeles Ketamine MDMA

TALK TITLE
The Future of Psychedelic Medicine in Los Angeles

DESCRIPTION
Increasing access and availability to psychedelic-assisted psychotherapy means we are at the cusp of a revolution in the medical treatment of mental health issues. The current state of psychedelics within the fields of psychiatry and mental health will be presented, as well as the future for center based access to these medicines in Los Angeles in 2019 and beyond.

FEATURED MUSICAN - RACHEL KANN
Rachel Kann is a 2019 Inquiry Fellow through IJC-AJU and WORD Grant recipient.
Her poetry has been featured on Morning Becomes Eclectic on NPR and as The Weather on the podcast phenomenon, Welcome to Night Vale. She is the 2017 Outstanding Instructor of the Year at UCLA Extension Writers' Program. Her latest book, “How to Bless the New Moon” is forthcoming in fall 2019. She is initiated as Tzovah through Kohenet and apprenticed in ceremonial work under Sitaramaya Sita.
rachelkann.com

BIOS
Dr. Cole Marta is a psychiatrist in private practice at the California Center for Psychiatric Treatment (CCPT), where his clinic provides adult psychiatric care with a specialization in using ketamine for treatment-resistant Depression. He is also the founder of New School Research, a company that conducts clinical trials with a focus on psychedelic research. He is the principal investigator at the Los Angeles site of phase II and III trials using MDMA-assisted psychotherapy for PTSD for the study sponsor, Multidisciplinary Association for Psychedelic Studies (MAPS).

Brooke Balliett, LMFT, is a licensed marriage and family therapist and board registered psychological assistant in Los Angeles, CA. With over a decade of clinical experience in trauma, developmental and depth psychology, Brooke has a passion for treating psychological, spiritual, emotional and relationship challenges through the development of self awareness, emotional intelligence and recognition of the healing power we each inherently hold inside of us. Brooke is a therapist on the Los Angeles MAPS Phase 3 clinical trial of MDMA-assisted psychotherapy for the treatment of PTSD, a psychotherapist specializing in emotional intelligence, Ketamine-Assisted Psychotherapy and Jungian psychotherapy, and also provides direct service, supervision and training in harm reduction services at events worldwide with the Zendo Project, Kosmicare and RGX Medical. Additionally, she provides clinical supervision in depth psychotherapy, ketamine-assisted psychotherapy and psychedelic integration for early career psychotherapists.